Microthrombus formation on hemodialysis membranes: a placebo controlled randomized trail of two doses of Indobufen.
The role of Indobufen in preventing the formation of microthrombi on hemodialysis membranes has been investigated in 18 patients in a placebo controlled randomized double-blind cross-over study. All patients had been on regular maintenance hemodialysis for at least 3 months. Indobufen was given as 100 mg b.d. and 200 mg b.d. each for a 7 day period with a 7 day wash-out period between the treatments. Both Indobufen regimens prevented the fall in platelet count, reduced the increase in plasma BTg levels during dialysis, increased the post dialysis plasma heparin levels (p less than 0.05) and inhibited pre-dialysis platelet aggregation with collagen (p less than 0.05), when compared with placebo treatment. Scanning electron microscopy demonstrated minimal fibrin and reduced platelet deposition following Indobufen treatment. There was no difference in the effect of 100 mg b.d. and 200 mg b.d. Indobufen doses. The drug was well tolerated, despite the relatively high levels measured, only one patient withdrew because of side effects. This study indicates that Indobufen when added to a routine hemodialysis treatment schedule, can significantly reduce platelet activation and the thrombus formation on the hemodialysis membranes.
D001792:Blood Platelets / Q000187:drug effects* / Q000502:physiology; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D005337:Fibrin; D006801:Humans; D054833:Isoindoles; D007676:Kidney Failure, Chronic / Q000097:blood / Q000628:therapy; D008297:Male; D008567:Membranes, Artificial; D010654:Phenylbutyrates / Q000008:administration & dosage* / Q000494:pharmacology; D010973:Platelet Adhesiveness / Q000187:drug effects; D011897:Random Allocation; D006435:Renal Dialysis / Q000379:methods*; D013927:Thrombosis
D054833:Isoindoles; D008567:Membranes, Artificial; D010654:Phenylbutyrates; C020371:indobufen; D005337:Fibrin